Oxygen Biotherapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 19   

Articles published

OXBT 3.97 -0.03 (-0.75%)
price chart
Worth Watching Stocks: Oxygen Biotherapeutics, Inc. (OXBT), Synergy ...
Manhattan, NY- June 24, 2014 - (Techsonian) - Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company, involve in developing biotechnology products that deliver oxygen to target tissues in the body first and foremost in the United ...
Related articles »  
Stocks to Keep Your Eyes on - Oxygen Biotherapeutics, Inc.(NASDAQ:OXBT ...
Las Vegas, NV - June 24, 2014 - (TechSonian) �Oxygen Biotherapeutics, Inc.(NASDAQ:OXBT) a development stage company, involve in developing biotechnology products that deliver oxygen to target tissues in the body first and foremost in the United ...
Related articles »  
Fast Moving Stocks: Facebook Inc (NASDAQ:FB), Zynga Inc (NASDAQ:ZNGA ...
On 9 july 2014 Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, highlighted three recent review articles examining the current ...
Morning Buzz: Celgene Corporation (NASDAQ:CELG), CTI BioPharma Corp ...
(NASDAQ:CTIC), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT). Celgene Corporation (NASDAQ:CELG)'s shares gained 0.29% to $88.64.
Related articles »  
Data points: Economic calendar
... Lorillard Inc., Magellan Health Inc., Marinemax Inc., Medidara Solutions, Meridean Biosciences, Minerals Technologies, Monro Muffler, Moody's Corp.
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in ...
MORRISVILLE, N.C., Jul 09, 2014 (BUSINESS WIRE) -- Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three ...
Related articles »  
Worth Watching Stocks: Glu Mobile Inc. (GLUU), Alpha Natural Resources, Inc ...
Glu Mobile Inc. (NASDAQ:GLUU) opened the session at $3.89, trading in a range of $3.81 - $3.91, and closed at $3.85. The stock showed a negative performance of -1.79% in the last trading session.
Related articles »  
Bellerophon Therapeutics Completes Enrollment of its Phase 2 Trial of INOpulse ...
HAMPTON, NJ, USA I June 26, 2014 I Bellerophon Therapeutics LLC, a clinical stage biotherapeutics company, today announced that it has completed enrollment of its 159-patient Phase 2 clinical trial of INOpulse for the treatment of pulmonary ...
Related articles »